Created with sketchtool.

In HR+, HER2+ early-stage disease:

Neratinib (NERLYNX) is included as a treatment option in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer26

Category 2A

Neratinib (NERLYNX)

Treatment option for extended adjuvant therapy, following adjuvant trastuzumab-containing therapy, in HR+, HER2+ early stage patients with a perceived high risk of recurrence

Explore ExteNET Study Designs

NCCN makes no warranties of any kind whatsoever regarding its content, use, or application and disclaims any responsibility for how its content is applied or used, in any way.

NCCN: National Comprehensive Cancer Network.

IMPORTANT SAFETY INFORMATION

NERLYNX® (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS: The most common adverse reactions (reported in ≥5% of patients) were:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

For Full Prescribing Information, please click here.